Harvard Molecular Diagnostics: Current Roles in Cancer Diagnosis 2026

Master the Latest Advances in Molecular Oncology and Precision Cancer Diagnostics

Harvard Molecular Diagnostics: Current Roles in Cancer Diagnosis 2026 is an advanced educational program designed to provide pathologists, oncologists, molecular diagnosticians, laboratory directors, and precision medicine specialists with a comprehensive review of contemporary molecular cancer diagnostics. Developed by leading faculty from Harvard Medical School and affiliated institutions, this course explores the rapidly evolving role of molecular pathology in cancer diagnosis, prognosis, treatment selection, and personalized patient care.

Through expert-led lectures, real-world case discussions, and practical laboratory applications, participants gain a deep understanding of modern molecular technologies including next-generation sequencing (NGS), liquid biopsy, circulating tumor DNA (ctDNA), bioinformatics, tumor profiling, and emerging biomarkers that are transforming oncology practice.

The program emphasizes the integration of molecular findings into clinical decision-making while addressing practical challenges related to test selection, interpretation, implementation, reimbursement, and accessibility in modern healthcare systems.

---

Course Overview

Molecular diagnostics has become an essential component of modern cancer care. Advances in genomic technologies now allow clinicians to identify actionable mutations, predict therapeutic response, monitor disease progression, and guide personalized treatment strategies across a wide range of malignancies.

This comprehensive course reviews the scientific foundations, clinical applications, and practical implementation of molecular oncology in routine patient care. Participants learn how molecular testing informs precision medicine, improves diagnostic accuracy, and supports individualized treatment planning across both solid tumors and hematologic malignancies.

Special emphasis is placed on emerging technologies, evolving biomarkers, and real-world applications that are shaping the future of cancer diagnosis and management.

---

Comprehensive Curriculum

Molecular Oncology Foundations

Participants review the core principles of molecular cancer diagnostics, including:

• Cancer genomics
• Somatic mutations
• Germline mutations
• Oncogenes and tumor suppressor genes
• Molecular pathways in cancer
• Precision oncology principles
• Companion diagnostics
• Biomarker-driven treatment strategies

The course establishes a strong foundation for understanding modern molecular testing methodologies.

---

Next-Generation Sequencing (NGS)

Extensive coverage includes:

• NGS workflow and methodology
• Targeted sequencing panels
• Whole exome sequencing
• Whole genome sequencing
• RNA sequencing
• Variant detection and classification
• Quality control procedures
• Clinical interpretation of genomic findings

Participants gain practical insight into implementing and interpreting NGS assays in clinical laboratories.

---

Bioinformatics in Molecular Diagnostics

Topics include:

• Data analysis pipelines
• Variant calling
• Annotation systems
• Quality assessment
• Clinical reporting
• Genomic databases
• Artificial intelligence applications
• Computational challenges in molecular pathology

Faculty explain how bioinformatics supports accurate genomic interpretation and precision medicine.

---

Liquid Biopsy and Circulating Tumor DNA

Participants explore:

• Circulating tumor DNA (ctDNA)
• Cell-free DNA analysis
• Minimal residual disease (MRD) monitoring
• Early cancer detection
• Treatment response assessment
• Disease surveillance
• Resistance mutation detection

The course reviews the rapidly expanding role of liquid biopsy technologies in oncology.

---

Solid Tumor Molecular Diagnostics

Coverage includes molecular testing strategies for:

• Lung cancer
• Breast cancer
• Colorectal cancer
• Melanoma
• Prostate cancer
• Ovarian cancer
• Pancreatic cancer
• Brain tumors
• Rare solid malignancies

Participants learn how genomic alterations influence diagnosis, prognosis, and targeted therapy selection.

---

Hematologic Malignancies

Topics include:

• Leukemia molecular profiling
• Lymphoma genomics
• Myelodysplastic syndromes
• Myeloproliferative neoplasms
• Minimal residual disease testing
• Molecular monitoring
• Targeted therapeutic approaches

Faculty discuss molecular testing applications across hematologic cancers.

---

Predictive and Prognostic Biomarkers

Participants review:

• EGFR mutations
• ALK rearrangements
• KRAS mutations
• BRAF mutations
• HER2 amplification
• BRCA mutations
• Microsatellite instability (MSI)
• Tumor mutational burden (TMB)
• PD-L1 testing

Special emphasis is placed on biomarkers that guide treatment selection.

---

Precision Medicine and Targeted Therapy

Coverage includes:

• Molecularly targeted therapies
• Precision oncology workflows
• Personalized treatment planning
• Resistance mechanisms
• Emerging targeted agents
• Clinical trial matching
• Companion diagnostics

Participants learn how molecular findings influence therapeutic decision-making.

---

Molecular Pathology Laboratory Management

Practical discussions include:

• Laboratory implementation
• Test validation
• Quality assurance
• Regulatory compliance
• Cost-effectiveness
• Reimbursement challenges
• Workflow optimization
• Laboratory leadership strategies

This section is particularly valuable for laboratory directors and administrators.

---

Emerging Technologies and Future Directions

The course highlights cutting-edge innovations including:

• Artificial intelligence in molecular diagnostics
• Multi-omics integration
• Single-cell sequencing
• Spatial transcriptomics
• Novel biomarker discovery
• Early cancer detection technologies
• Future precision oncology applications

Participants gain insight into technologies expected to shape the next generation of cancer diagnostics.

---

Learning Objectives

Upon completion of this course, participants will be able to:

• Explain the scientific principles underlying molecular cancer diagnostics.
• Interpret molecular test results and integrate findings into patient care.
• Utilize next-generation sequencing technologies effectively in oncology practice.
• Apply liquid biopsy technologies for diagnosis, monitoring, and treatment assessment.
• Select appropriate molecular tests for specific clinical scenarios.
• Evaluate predictive and prognostic biomarkers in cancer management.
• Communicate molecular diagnostic findings effectively within multidisciplinary teams.
• Understand practical considerations related to implementation, reimbursement, and access.
• Integrate emerging molecular technologies into precision oncology practice.
• Improve patient outcomes through personalized diagnostic and therapeutic strategies.

---

Educational Features

✔ 40 Expert Video Lectures

✔ 40 Subtitle Files (.VTT)

✔ 41 Comprehensive PDF Presentations

✔ Harvard Faculty Instruction

✔ Next-Generation Sequencing Review

✔ Liquid Biopsy Applications

✔ Precision Oncology Updates

✔ Bioinformatics Training

✔ Molecular Pathology Best Practices

✔ Biomarker Interpretation

✔ Clinical Case Discussions

✔ Evidence-Based Cancer Diagnostics

---

Target Audience

This course is designed for:

• Pathologists
• Molecular Pathologists
• Medical Oncologists
• Hematologist-Oncologists
• Laboratory Directors
• Clinical Geneticists
• Precision Medicine Specialists
• Pathology Residents
• Pathology Fellows
• Oncology Fellows
• Clinical Laboratory Scientists
• Healthcare Professionals Involved in Cancer Diagnostics

---

Why This Course Stands Out

Harvard Molecular Diagnostics: Current Roles in Cancer Diagnosis 2026 provides a comprehensive and practical review of modern molecular oncology. Combining foundational molecular biology, advanced genomic technologies, bioinformatics, liquid biopsy applications, biomarker interpretation, and precision medicine strategies, the program equips participants with the knowledge and skills necessary to navigate the rapidly evolving landscape of cancer diagnostics and personalized oncology care.

4. Topics

1. 01 Integrated Molecular Oncology in 2026 Trends and Tools for Gene Fusion Detection

2. 02 End-to-end Process to Accelerating Treatment Initiation with Next-day NGS

3. 03 Translation of Molecular to Immunohistochemistry

4. 04 Informatics Architecture

5. 05 NGS Pipelines Demystified Practical Bioinformatics

6. 06 Tumor Mutation Burden, MSI, and HRD

7. 07 Indel Detection

8. 08 Viral Sequence Detection and Other Signatures

9. 09 Gene Fusion Detection and Interpretation by RNA-based NGS a Practical, Cased-based Approach

10. 10 Additional Informatics Analyses Detection of Clinically Significant Isoforms and Sub-gene Events through RNA andor DNA-based NGS

11. 11 Oncogenicity Interpretation of Gene Fusions Detected by RNA-based NGS

12. 12 Applications of Long-Read Sequencing for Cancer Diagnostics

13. 13 Liquid Biopsy and ctDNA Technical and Clinical Perspectives

14. 14 Panel Discussion Tissue vs Liquid Biopsy

15. 15 Sarcoma and Fusion Testing

16. 16 Molecular Diagnostics for GYN Tumors

17. 17 Molecular Diagnostics for Pediatric Tumors

18. 18 GU Cancers Molecular Markers (Only PDF, No Video)

19. 19 Copy Number Variation via NGS and Microarray

20. 20 Cytogenomics Technical Focus

21. 21 Cytogenomics Clinical Focus

22. 22 Gliomas and Methylation Profiling

23. 23 Germline Testing in Oncology What, When, and How

24. 24 Tumor-Normal Paired Sequencing Clinical Impact

25. 25 Case Review Pathology Oncology Perspectives

26. 26 Melanoma Molecular Pathology

27. 27 Molecular Diagnostics for Breast Cancer

28. 28 Tumor Board Simulation Real Case Review

29. 29 Myeloid Neoplasms and MRD Testing

30. 30 Leukemia Molecular Diagnostics (B- and T-cell)

31. 31 Molecular Diagnostics and Lymphoma

32. 32 Pharmacogenomics in Oncology Management

33. 33 Lung Tumor Testing

    34. GI Cancer Case-Based Applications VIDEO + PDF Not Release

34. 35 Thyroid Cancer and Salivary Tumor Genomics

35. 36 AI in Molecular Oncology

36. 37 Interactive Workshop Case Report Writing and Communication

37. 38 The Power of Patient Partnership in Cancer Advocacy

38. 39 Building a Molecular Profiling Program

39. 40 Regulatory and Reimbursement Essentials

40. 41 Lab Leadership and Challenges

41. 42 Future Directions in Molecular Oncology